Global Gene Therapy Market Size, Share, Growth Analysis, By Vector(Lentivirus, AAV), By Indication(Acute Lymphoblastic Leukemia (ALL), Inherited Retinal Disease) - Industry Forecast 2024-2031

Report ID: SQMIG35H2218 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 73 | Figures: 75

Global Gene Therapy Market Insights

Gene Therapy Market size was valued at USD 6.39 Billion in 2021 and is poised to grow from USD 7.60 Billion in 2022 to USD 38.34 Billion by 2030, at a CAGR of 19% during the forecast period (2023-2030).

The global gene therapy market is a rapidly growing market that is poised for significant growth in the coming years. The purpose of the gene therapy market is to provide a cure for genetic disorders that are currently untreatable. Gene therapy market is focused on developing new and innovative therapies that can address the root cause of these diseases.

The key driving factors for the gene therapy market is the increasing prevalence of genetic disorders. The prevalence of genetic disorders is increasing globally, which is driving the demand for gene therapy. The main restraints for the gene therapy market are the high cost of these therapies. Gene therapies are complex and expensive to develop, which results in high costs for patients. The delivery mechanism is critical for the success of gene therapies, as it needs to deliver the healthy gene to the targeted cells in the body. Additionally, the immune system can recognize the gene therapy as a foreign invader, which can lead to an immune response that reduces the effectiveness of the therapy. The gene therapy market presents a significant opportunity for pharmaceutical companies to develop new and innovative therapies.

US Gene Therapy Market is poised to grow at a sustainable CAGR for the next forecast year.

Global Gene Therapy Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

The global gene therapy market is highly competitive with a large number of players operating in the industry. The key players in the market are focusing on the development of new and advanced therapies to enhance their market presence. The gene therapy market is highly competitive, with a number of players focusing on the development of novel therapies for the treatment of a range of diseases. The market is expected to continue to grow in the coming years, driven by increasing investment in R&D and growing demand for new and advanced therapies for the treatment of rare and life-threatening diseases. 'Novartis International AG (Switzerland)', 'Pfizer Inc. (US)', 'Biogen Inc. (US)', 'Spark Therapeutics Inc. (US)', 'Sarepta Therapeutics Inc. (US)', 'bluebird bio-Inc. (US)', 'Gilead Sciences Inc. (US)', 'Amgen Inc. (US)', 'Regenxbio Inc. (US)', 'Krystal Biotech Inc. (US)', 'uniQure N.V. (Netherlands)', 'Avexis Inc. (US)', 'Orchard Therapeutics plc (UK)', 'Abeona Therapeutics Inc. (US)', 'Solid Biosciences Inc. (US)', 'Audentes Therapeutics Inc. (US)', 'Adaptimmune Therapeutics plc (UK)', 'Intellia Therapeutics Inc. (US)', 'Editas Medicine Inc. (US)', 'Precision BioSciences Inc. (US)'

Genetic disorders, such as spinal muscular atrophy, cystic fibrosis, and hemophilia, are on the rise worldwide. The increasing prevalence of these disorders is driving the growth of the gene therapy market, as gene therapies have shown promising results in the treatment of these disorders.

Increased focus on rare diseases: Gene therapy is becoming increasingly popular for the treatment of rare genetic disorders, which were previously ignored due to their low prevalence. For example, Zolgensma, a gene therapy for spinal muscular atrophy, was approved by the FDA in 2019 and has since become a popular treatment option. Similarly, Luxturna, a gene therapy for inherited retinal disease, was approved in 2017.

In 2022, North America emerged as the dominant region in the gene therapy market, contributing to over 65.0% of the overall revenue. It is projected to remain the largest routine manufacturer of gene therapy drugs during the forecast period, with increasing investments in R&D by companies of all sizes. The market is being driven by rising government investments and the growing prevalence of targeted diseases in the region, such as spinal muscular atrophy, affecting 10,000 to 25,000 individuals in the U.S. alone, according to the Spinal Muscular Atrophy Foundation.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Global Gene Therapy Market Size, Share, Growth Analysis, By Vector(Lentivirus, AAV), By Indication(Acute Lymphoblastic Leukemia (ALL), Inherited Retinal Disease) - Industry Forecast 2024-2031

Global Gene Therapy Market Insights

Global Gene Therapy Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Gene Therapy Market?

Who are the key vendors in the Global Gene Therapy Market?

What is the key driver of Global Gene Therapy Market?

What is the key market trend for Global Gene Therapy Market?

Which region accounted for the largest share in Global Gene Therapy Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300